BP, VT and RE) and with IXE Q2W for PCS, MCS, and 7/8 domains (except MH) (post hoc). Within the same subgroup, a greater percentage of pts in each of the 3 active groups reported SF-36 scores ≥normative values at Wk 24 vs PBO, with statistical significance for PCS, MCS, and majority of the individual domains (Table) (post hoc). 
Conclusions:
In pts with active PSA, both IXE and ADA treatment groups reported significant improvements in pt-reported health status as assessed by SF-36 and the majority of its individual domains, both in the general trial population, and in the subgroup of pts with baseline scores <A/G norms. Objectives: To evaluate patient-reported outcomes (PROs) in patients (pts) with active PsA enrolled in OPAL Broaden (N=422) and OPAL Beyond (N=394). OPAL Broaden pts had an inadequate response (IR) to ≥1 conventional synthetic disease-modifying antirheumatic drug and were naïve to tumour necrosis factor inhibitors (TNFi) whilst OPAL Beyond pts had an IR to ≥1 TNFi. Methods: Pts were randomised to tofacitinib 5 mg twice daily (BID), tofacitinib 10 mg BID, placebo (PBO)→ tofacitinib 5 mg BID, PBO→ tofacitinib 10 mg BID and, in OPAL Broaden, also to adalimumab 40 mg subcutaneously every two weeks (active comparator). Pts receiving PBO advanced to either tofacitinib 5 mg BID or 10 mg BID at month 3 (M3) (Table 1) . Greater improvements in PtGA and Arthritis Pain were observed as early as Week 2 through M3 with both tofacitinib doses compared with PBO in both studies (p≤0.05). Greater improvements were also reported in SF-36 Physical Component Summary, DLQI and ASQOL scores at M1 and M3 with both tofacitinib doses compared with PBO (p≤0.05). There were greater improvements in SF-36 physical functioning, bodily pain and vitality domains with both tofacitinib doses compared with PBO in both studies (p≤0.05) at M3. SF-36 social functioning domain showed greater improvement with tofacitinib 5 mg BID in OPAL Broaden and both tofacitinib doses in OPAL Beyond compared with PBO at M3 (p≤0.05). SF-36 role-physical domain showed greater improvement with tofacitinib 10 mg BID in OPAL Beyond at M3 compared with PBO (p≤0.05). FACIT-F showed a greater improvement in both studies at M3 with both tofacitinib doses compared with PBO (p≤0.05). In OPAL Broaden, improvements in PROs were similar between tofacitinib and adalimumab.
Conclusions: Pts with active PsA receiving tofacitinib reported greater improve-
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AB0795 OSTEOARTHRITIS AND COMORBIDITY: ASSOCIATION BETWEEN MENTAL FEATURES AND CYTOKINES LEVELS
E. Trifonova, O. Sazonova, E. Zonova. Novosibirsk State Medical University, Novosibirsk, Russian Federation
Background: Studies of mental health in patients with osteoarthritis (OA) are topical at the present time. This applies especially to OA patients with such comorbidity as obesity, metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM). Psychological features, quality of life (QoL) and depression degree also can be linked with immunopathogenesis of OA with obesity, MS, T2DM. Objectives: To explore the mental health in knee OA patients with obesity, MS, T2DM and to estimate association between psychological and immunological features. Methods: Patients (n=128) with bilateral knee OA according to ACR criteria were divided into four groups. Group 1 (n=17) had obesity, group 2 (n=17) had MS, group 3 (n=56) had T2DM and group 4 (n=38) had only knee OA without comorbidity. All patients were comparable by age, sex and duration of OA. We assessed serum cytokine levels (IL-1b, IL-6, IL-10, IL-18), NO and adipokines (adiponectin, leptin) using ELISA. The parameters of QoL, mental health and depression degree were measured by short form 36 (SF-36), Knee injury and Osteoarthritis Outcome Score -(KOOS) and with patient health questionnaire-9 (PHQ-9). We also studied coping strategies to overcome pain by Coping Strategy Questionnaire (CSQ). U-Mann-Whitney test was applied to detect differences between groups. Correlation was assessed using Spearman correlation coefficient (r s ). Results: During comparative analysis, we found many statistically significant differences in such indexes and questionnaires as SF-36, KOOS, PHQ-9, CSQ between groups knee OA patients with comorbidity and group knee OA patients without concomitant diseases. Patients with OA and obesity were characterized by low values of mental health (SF-MH) (median (Me) 52; interquartile range (IQR) 38-64; p=0.01). Patients from group 2 (MS) and 3 (T2DM) had significant impairment of QoL parameters, mental health values. Patients of these groups also had the higher degree of depression and built coping strategies to overcome pain of OA worse than patients of OA group. Differences in serum cytokine levels were found in patients with OA and T2DM (IL-6 p=0.0018; IL-18 p=0.0006; NO p<0.001). Significant high leptin level had OA patients with obesity (p=0.03) and OA patients with T2DM (p=0.0002). Correlation analysis identified the association between mental health and cytokines in OA patients with obesity and OA patients with T2DM. Some data are presented (Table) . Conclusions: This study suggests that OA patients with obesity, MS and T2DM have special mental features which may be linked with immunological parameters. This data should be verified by larger studies and can be the part for an integrated program of treatment and rehabilitation of OA patients with comorbidity. 
Background:
The influence of different interleukins on development and progression of osteoarthritis (OA) has been proved. However, there is lack of data on relationship between mental health and immunological features in OA patient with type 2 diabetes mellitus (T2DM). Objectives: To estimate the relationship between mental health and the proinflammatory serum cytokine levels in patients with knee OA and T2DM depending on glycemic control. Methods: A study was performed on 45 persons who had bilateral knee OA according to the ACR criteria and T2DM. Then patients were divided into two groups according to the compensation degree T2DM taking into account parameters of glycated hemoglobin concentrations (HbA1c) which were assessed using liquid chromatography. Group 1 (n=26) had controlled T2DM. Group 2 (n=19) had uncontrolled T2DM. All patients were comparable by age, sex and duration of OA. Serum cytokine levels (IL-1b, IL-6, IL-10, IL-18), NO, and adypokines (adiponectin, leptin) using ELISA were measured. Blood glucose level was also estimated. The parameters of QoL, mental health, depression degree and coping strategies to overcome pain were measured by short form 36 (SF-36), Knee injury and Osteoarthritis Outcome Score -(KOOS) and with patient health questionnaire-9 (PHQ-9), Coping Strategy Questionnaire (CSQ). We used U-Mann-Whitney tests to detect differences between selected groups. Correlation was assessed using Spearman correlation coefficient (r s ). Results: Patients with OA and uncontrolled T2DM had significant low values of role limitations due to emotional problems (SF-RE) (median (Me) 38; interquartile range (IQR) 25-52.3; p=0.02). Serum cytokines levels were not different between studied groups. Correlation analysis identified the relationships between parameters of mental health and serum cytokine levels in OA patients with uncontrolled T2DM. Certain data are presented (Table) .
Conclusions:
It follows from these results mental and immunology parameters of OA patients with uncontrolled T2DM can be linked. Such interleukins as IL-6 and IL-10 may play a role of potential biomarkers of mental impairment in this category of patients. These data should be verified by larger studies and may allow in future to develop programs of treatment and rehabilitation of OA patients with uncontrolled T2DM within personalized medicine. 
